Marc A. Pfeffer

6 ta ish

Brigham and Women's Hospital

1. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

   Salim Yusuf, Marc A. Pfeffer, Karl Swedberg +6

   Maqola20032 iqtibos

   ABIABI:AkademIndex/2026.other.295765

2. Spironolactone for Heart Failure with Preserved Ejection Fraction

   Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann +20

   Maqola20142 iqtibos

   ABIABI:AkademIndex/2026.other.295781

3. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

   Scott D. Solomon, John J.V. McMurray, Inder S. Anand +31

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295865

4. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

   Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett +22

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295867

5. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

   Amil M. Shah, Brian Claggett, Nancy K. Sweitzer +6

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.613467

6. VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial

   Frank M. Sacks, Petar Alaupovic, Lemuel A. Moyé +5

   Maqola20002 iqtibos

   ABIABI:AkademIndex/2026.other.673054